Baseline characteristics of all individuals and by treatment response status (responders vs nonresponders) to EBVST treatment
| Characteristic . | Overall, N = 56 (%) . | Treatment response, n (%) . | P value∗ . | |
|---|---|---|---|---|
| Responders, n = 36 (64%) . | Nonresponders, n = 20 (36%) . | |||
| Sex | ||||
| Female | 17 (30%) | 10 (28%) | 7 (35%) | .6 |
| Male | 39 (70%) | 26 (72%) | 13 (65%) | |
| Age groups | ||||
| 0-30 years | 24 (43%) | 17 (47%) | 7 (35%) | .6 |
| 31-60 years | 21 (38%) | 12 (33%) | 9 (45%) | |
| 61-100 years | 11 (20%) | 7 (19%) | 4 (20%) | |
| Ethnic groups | ||||
| Hispanic | 12 (21%) | 9 (25%) | 3 (15%) | .5 |
| Non-Hispanic | 44 (79%) | 27 (75%) | 17 (85%) | |
| Diagnosis | ||||
| T-cell lymphomas | 13 (23%) | 8 (22%) | 5 (25%) | .7 |
| Hodgkin disease | 19 (34%) | 14 (39%) | 5 (25%) | |
| Burkitt/large cell lymphoma | 13 (23%) | 7 (19%) | 6 (30%) | |
| Other | 11 (20%) | 7 (19%) | 4 (20%) | |
| Characteristic . | Overall, N = 56 (%) . | Treatment response, n (%) . | P value∗ . | |
|---|---|---|---|---|
| Responders, n = 36 (64%) . | Nonresponders, n = 20 (36%) . | |||
| Sex | ||||
| Female | 17 (30%) | 10 (28%) | 7 (35%) | .6 |
| Male | 39 (70%) | 26 (72%) | 13 (65%) | |
| Age groups | ||||
| 0-30 years | 24 (43%) | 17 (47%) | 7 (35%) | .6 |
| 31-60 years | 21 (38%) | 12 (33%) | 9 (45%) | |
| 61-100 years | 11 (20%) | 7 (19%) | 4 (20%) | |
| Ethnic groups | ||||
| Hispanic | 12 (21%) | 9 (25%) | 3 (15%) | .5 |
| Non-Hispanic | 44 (79%) | 27 (75%) | 17 (85%) | |
| Diagnosis | ||||
| T-cell lymphomas | 13 (23%) | 8 (22%) | 5 (25%) | .7 |
| Hodgkin disease | 19 (34%) | 14 (39%) | 5 (25%) | |
| Burkitt/large cell lymphoma | 13 (23%) | 7 (19%) | 6 (30%) | |
| Other | 11 (20%) | 7 (19%) | 4 (20%) | |
Pearson χ2 test; Fisher's exact test.